High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer - a phase I/II study
1996

High-Dose Chemotherapy for Metastatic Breast Cancer

Sample size: 32 publication Evidence: moderate

Author Information

Author(s): DA Cameron, J Craig, H Gabral, L Lee, J MacKay, AC Parker, RCF Leonard

Primary Institution: Western General Hospital, Edinburgh, UK

Hypothesis

Can high-dose chemotherapy supported by peripheral blood progenitor cells improve outcomes in women with poor prognosis metastatic breast cancer?

Conclusion

The study found that peripheral blood progenitor cell mobilization and support of high-dose chemotherapy is feasible and can lead to improved survival in patients with metastatic breast cancer.

Supporting Evidence

  • PBPC mobilization was successful in 88% of patients.
  • The median survival from the start of induction chemotherapy was 15 months.
  • There were no treatment-related deaths reported.

Takeaway

Doctors tested a new way to help women with advanced breast cancer live longer by using special blood cells to support strong chemotherapy, and it worked for many of them.

Methodology

The study involved 32 women who received high-dose chemotherapy after an induction regimen, with peripheral blood progenitor cells mobilized using cyclophosphamide and G-CSF.

Potential Biases

There may be selection bias due to the small number of patients and the nature of the treatment regimens.

Limitations

The study had a small sample size and did not determine the optimum drug combination for treatment.

Participant Demographics

The median age of participants was 39 years, with a range from 27 to 55 years.

Statistical Information

P-Value

0.054

Confidence Interval

0-9%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication